Education
About Us
Working with TipRanks
Follow Us
ProMIS Neurosciences (PMN)
NASDAQ:PMN
PMN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.47 - $2.37
Previous CloseN/A
Volume32.49K
Average Volume (3M)49.69K
Market Cap
$16.51M
Enterprise Value$3.12M
Total Cash (Recent Filing)$13.32M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.48
Next Earnings
Aug 18, 2025EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding32,689,190
10 Day Avg. Volume76,133
30 Day Avg. Volume49,685
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)0.79
Price to Sales (P/S)0.00
P/FCF Ratio-0.61
Enterprise Value/Market Cap0.19
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.27
Forecast
1Y Price Target
$4.50Price Target Upside749.06% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
ProMIS Neurosciences News
PremiumCompany Announcements
ProMIS Neurosciences Reports Q1 2025 Progress and Financials
PremiumCompany Announcements
ProMIS Neurosciences Reports 2024 Financial Turnaround
PremiumPre-Earnings
Is PMN a Buy, Before Earnings?---
Bulls Say, Bears Say
Bulls Say
Antibody DevelopmentPreclinical studies demonstrate superior binding of PMN310 compared to other amyloid drugs.
Financial StabilityProMIS has $13.3M in cash and access to an additional $10.4M, ensuring financial runway through interim data periods.
Bears Say
Clinical Trial TimelineThe first-in-patient P1b data for PMN310 is not expected until 2026, delaying potential proof-of-concept.
---
PMN FAQ
What was ProMIS Neurosciences’s price range in the past 12 months?
ProMIS Neurosciences lowest stock price was $0.47 and its highest was $2.37 in the past 12 months.
What is ProMIS Neurosciences’s market cap?
ProMIS Neurosciences’s market cap is $16.51M.
When is ProMIS Neurosciences’s upcoming earnings report date?
ProMIS Neurosciences’s upcoming earnings report date is Aug 18, 2025 which is in 93 days.
How were ProMIS Neurosciences’s earnings last quarter?
Currently, no data Available
Is ProMIS Neurosciences overvalued?
According to Wall Street analysts ProMIS Neurosciences’s price is currently Undervalued.
Does ProMIS Neurosciences pay dividends?
ProMIS Neurosciences does not currently pay dividends.
What is ProMIS Neurosciences’s EPS estimate?
ProMIS Neurosciences’s EPS estimate is -0.16.
How many shares outstanding does ProMIS Neurosciences have?
ProMIS Neurosciences has 32,689,190 shares outstanding.
What happened to ProMIS Neurosciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of ProMIS Neurosciences?
Currently, no hedge funds are holding shares in PMN
---
ProMIS Neurosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.50 (749.06% Upside)
$4.50 (749.06% Upside)
Insider Transactions
Bought Shares
Worth $14.6K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-70.55%
12-Months-Change
Fundamentals
Return on Equity
-19.56%
Trailing 12-Months
Asset Growth
284.60%
Trailing 12-Months
Company Description
ProMIS Neurosciences
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
---
PMN Stock 12 Month Forecast
Average Price Target
$4.50
▲(749.06% Upside)
Technical Analysis
Minerva Neurosciences
―
Bolt Biotherapeutics
―
Cognition Therapeutics
―
Neurosense Therapeutics Ltd.
―
Jupiter Neurosciences, Inc.
―
---